Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q70CQ3
UPID:
UBP30_HUMAN
Alternative names:
Deubiquitinating enzyme 30; Ubiquitin thioesterase 30; Ubiquitin-specific-processing protease 30
Alternative UPACC:
Q70CQ3; Q8WTU7; Q96JX4; Q9BSS3
Background:
Ubiquitin carboxyl-terminal hydrolase 30, also known as Deubiquitinating enzyme 30, plays a pivotal role in mitochondrial health by inhibiting mitophagy through deubiquitinating proteins targeted by parkin. It specifically targets 'Lys-6'- and 'Lys-11'-linked polyubiquitin chains, crucial for mitophagic signaling, and regulates mitochondrial fusion by acting on MFN1 and MFN2.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 30 could open doors to potential therapeutic strategies, especially in diseases where mitophagy and mitochondrial dynamics are disrupted.